Table 3.
Previous studies looking at prostate cancer incidence in Lynch syndrome
| Reference | Place | N (PrCa) | SIR/SRR | 95% CI | Median age at Dx | Gene involved |
|---|---|---|---|---|---|---|
| Aarnio et al.2 a | Finland | 360 (4) | SIR 2.9 | 0.8–7.4 | NR | NR |
| Scott et al.10 | Wales | 95 families (1) | SIR 1.02 | 0.1–13.6 | NR | MLH1 (0), MSH2 (1) |
| Goecke et al.24 | Germany | 259 (8) | NR | NR | 59 | MLH1 (0), MSH2 (8) |
| Grindedal et al.6 | Norway | 106 (9) | SIR 5.9 | 4.1–17.1 | 60.4 |
MLH1 (0), MSH2 (6), MSH6 (2), PMS2 (1) |
| Win et al.5b | Australia, Canada, United States |
382 (19) | SIR 2.05 | 1.23–3.01 | 64 |
MLH1 (3), MSH2 (15), MSH6 (1), PMS2 (0) |
| Pande et al.9 | MD Anderson | 151 (3) | SIR 0.93 | 0.19–2.7 | 65 | NR |
| Engel et al.8 | Germany, The Netherlands | 1,107 (17) | SIR 2.5 | 1.4–4.0 | 59 | NR |
| Raymond et al.7 | University of Michigan | 412 (15) | HR 1.99 | 1.31–3.03 | 65 | NR |
| This study | The Ohio State University | 188 (11) | SRR 4.87 | 2.43–8.71 | 64 |
MLH1 (1), MSH2 (7), MSH6 (2), PMS2 (1) |
CI, confidence interval; Dx, diagnosis; HR, hazard ratio; N, number; NR, not reported; PrCa, prostate cancer; SIR, standardized incidence ratio; SRR, standardized rate ratio.
a
Studied MLH1 (47 families) and MSH2 (3 families).
b
Studied patients who had a previous history of colorectal cancer.